MedTrace Logo

Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery

NCT00237328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1015

Last updated 2013-02-25

No results posted yet for this study

Summary

Heparin is a drug that is widely used to prevent and treat blood clotting. Individuals undergoing cardiopulmonary bypass surgery are administered high doses of heparin, and some of them develop antibodies to the drug. This immune response can lead to the formation of blood clots, setting the stage for a potential heart attack or stroke. The purpose of this study is to evaluate how often an immune response to heparin leads to the formation of blood clots in individuals who have had heart surgery.

Conditions

Interventions

DRUG

Heparin

Heparin will be used as the intra-operative anticoagulant

Sponsors & Collaborators

Principal Investigators

  • Thomas Ortel, MD, PhD · Duke University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-03-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00237328 on ClinicalTrials.gov